A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

被引：0
|
作者：
Ronen, O. [1 ]
Shickler, M. [2 ]
Reuveni, H. [2 ]
Israel, I. [2 ]
Haviv, I. [2 ]
Waymack, P. J. [2 ]
Cohen, E. [3 ]
机构：
[1] Galilee Med Ctr, Nahariyya, Israel
[2] Kitov Pharma, Tel Aviv, Israel
[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 106卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页码：1182 / 1183
页数：2
相关论文
共 50 条
  • [1] A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.
    Bessudo, Alberto
    Cohen, Ezra E. W.
    Gutierrez, Rodolfo
    Johnson, Daniel H.
    Rosenberg, Ari
    Sukari, Ammar
    Stemmer, Salomon M.
    Weinberg, Benjamin Adam
    Reuveni, Hadas
    Schickler, Michael
    Liang, Bertrand C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
  • [3] Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Rosenberg, Ari J.
    Kato, Shumei
    Johnson, Daniel
    Popovtzer, Aron
    Chiu, Vi K.
    Geva, Ravit
    Ben-David, Hava
    Meirson, Tomer
    Schickler, Michael
    Reuveni, Hadas
    CANCER RESEARCH, 2024, 84 (06)
  • [4] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study
    Chung, Christine
    Bonomi, Marcelo
    Steuer, Conor
    Schell, Michael
    Li, Jiannong
    Johnson, Matthew
    McMullen, Caitlin
    Wadsworth, J. Trad
    Patel, Krupal
    Kish, Julie
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James
    Saba, Nabil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of the interim safety analysis.
    Sacco, Assuntina Gesualda
    Messer, Karen
    Natsuhara, Amanda
    Chen, Ruifeng
    Wong, Deborah J. L.
    Worden, Francis P.
    Adkins, Douglas
    Pittman, Emily
    Zhang, Jing
    Daniels, Gregory A.
    Gold, Kathryn A.
    Espiritu, Maechelle
    Sutton, Brian
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
    Zandberg, D. P.
    Algazi, A.
    Jimeno, A.
    Good, J.
    Fayette, J.
    Bouganim, N.
    Ready, N.
    Clement, P.
    Goswami, T.
    Jarkowski, A.
    Armstrong, J.
    Asubonteng, K.
    Melillo, G.
    Mesia, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 13 - 13
  • [8] Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study
    Zandberg, D.
    Algazi, A.
    Jimeno, A.
    Good, J. S.
    Fayette, J.
    Bouganim, N.
    Ready, N.
    Clement, P. M.
    Goswmi, T.
    Jarkowski, A.
    Armstrong, J. M.
    Asubonteng, K.
    Melillo, G.
    Mesia, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [10] Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
    Gulati, Shuchi
    Crist, McKenzie
    Riaz, Muhammed Kashif
    Takiar, Vinita
    Lehn, Maria
    Monroe, Ilaina
    Palackdharry, Sarah
    Kurtzweil, Nicky
    Jandarov, Roman
    Harun, Nusrat
    Wise-Draper, Trisha M.
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1906 - 1915
12345